Data published in the Journal of the National Cancer Institute show that Evista (raloxifene) reduced the likelihood of developing invasive estrogen receptor positive breast cancer in high risk patients
Filed under: Nuclear Receptor | Tagged: Celvista, estrogen receptor, Evista, Lilly, Optruma, raloxifene, SERM
